Zm336372

Manufactured by Selleck Chemicals

ZM336372 is a laboratory equipment product designed for general laboratory use. It serves as a multipurpose tool that can be utilized in various scientific experiments and research activities. The core function of ZM336372 is to provide a reliable and versatile solution for laboratory tasks.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using zm336372

Antibody and Drug Reagents for EGFR, AXL, and MAPK Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies against EGFR (#2232, RRID:AB_331707), AXL (#8661, RRID:AB_11217435), phospho-ERK (#9101, RRID:AB_331646), ERK (#9102, RRID:AB_330744), PTEN (#9552, RRID:AB_10694066), β-actin (#4967, RRID:AB_330288), GAPDH (#2118, RRID:AB_561053), and vinculin, were obtained from Cell Signaling Technology. Anti-CBL (#05-440, RRID:AB_2290887) was obtained from MilliporeSigma. Anti-NF1 (A300-140A; RRID:AB_2149790) was obtained from Bethyl Antibodies. Vemurafenib, cobimetinib, neratinib, dabrafenib, trametinib, ZM336372, LY3009120, and belvarafenib were obtained from SelleckChem. Drugs for in vitro studies were dissolved in DMSO to create 10 or 100 mmol/L stock solutions and stored at −20°C.

Schreck K.C., Morin A., Zhao G., Allen A.N., Flannery P., Glantz M., Green A.L., Jones C., Jones K.L., Kilburn L.B., Nazemi K.J., Samuel D., Sanford B., Solomon D.A., Wang J., Pratilas C.A., Nicolaides T, & Mulcahy Levy J.M. (2021). Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma. Clinical Cancer Research, 27(22), 6197-6208.

+ Open protocol

+ Expand

RAS Pathway Inhibitor Effects on bFGF Depletion

Check if the same lab product or an alternative is used in the 5 most similar protocols

We examined effects of specific inhibitors related to RAS pathways (Favata et al., 1998 (link), Hall-Jackson et al., 1999 (link), Montagut et al., 2008 (link), Powis et al., 1994 (link), Sebolt-Leopold et al., 1999 (link), Vlahos et al., 1994 (link)) on bFGF-depletion assays and in vitro differentiation. PD184532 and wortmannin were purchased from Sigma. U0126 was obtained from Wako. ZM336372, AZ628, and LY294002 were purchased from Selleck. To exclude the effect of cell toxicity, the concentrations of each compound were selected at the range of lower than 80% cell growth inhibition judged by the percentage of nucleus number relative to the vehicle treatment in bFGF-depletion assays (Figures S5B–S5D).

Kubara K., Yamazaki K., Ishihara Y., Naruto T., Lin H.T., Nishimura K., Ohtaka M., Nakanishi M., Ito M., Tsukahara K., Morio T., Takagi M, & Otsu M. (2018). Status of KRAS in iPSCs Impacts upon Self-Renewal and Differentiation Propensity. Stem Cell Reports, 11(2), 380-394.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!